Trials / Completed
CompletedNCT00562406
Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Klinikum Ludwigshafen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this pilot study is to compare the functional and anatomic outcomes of chronic macular edema secondary to branch retinal vein occlusion (BRVO) treated with argon laser photocoagulation versus intravitreal ranibizumab (Lucentis®) injection versus a combination of both.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranibizumab | intravitreal injection of 0.5 mg ranibizumab after randomisation, at week 4 and 8 |
| PROCEDURE | Laser photocoagulation | laser photocoagulation to the retina at the area of edema |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2010-09-01
- Completion
- 2010-09-01
- First posted
- 2007-11-22
- Last updated
- 2011-07-22
Locations
4 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00562406. Inclusion in this directory is not an endorsement.